SPECIAL REPORT
While there is a growing consensus on the benefits of initiating treatment with a higher-efficacy (HE) disease-modifying therapy (DMT) in MS, there are a few considerations in clinical practice that need to be addressed. The key issues include the efficacy of HE DMTs relative to lower-efficacy therapies in slowing disability worsening; whether anti-CD20 monoclonal antibody agents (e.g. ofatumumab, ocrelizumab), which primarily target inflammatory disease activity, have an impact on progression independent of relapse activity (PIRA); how switching therapies may optimize outcomes; and whether long-term drug exposure is safe. Read More